1. Medical Department III, University Hospital of the Ludwig Maximilians University Munich, Munich, Germany;
2. Institute for Medical Informatics, Biometry and Epidemiology, Ludwig Maximilians University Munich, Munich, Germany;
3. Centre for Lymphoid Cancer, British Columbia Cancer Agency, Vancouver, BC, Canada;
4. Department of Clinical Pathology, Robert-Bosch-Krankenhaus, Stuttgart, Germany;
5. Dr. Margarete Fischer-Bosch-Institute of Clinical Pharmacology, Stuttgart, and University of Tübingen, Tübingen, Germany;
6. Hematopathology Section, University Hospital Schleswig-Holstein, Campus Kiel, Kiel, Germany;
7. Institute of Pathology, University of Würzburg, and Comprehensive Cancer Center Mainfranken, Würzburg, Germany;
8. Department of Medicine, Memorial Sloan Kettering Cancer Center, and Weill Medical College of Cornell University, New York, NY;
9. Wilmot Cancer Institute, University of Rochester, Rochester NY;
10. Division of Hematology, Mayo Clinic, Rochester, MN;
11. German Cancer Consortium and German Cancer Research Center, Heidelberg, Germany; and
12. Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA